TEE
ELVN icon

Tibra Equities Europe’s Enliven Therapeutics ELVN Stock Holding History

Tibra Equities Europe’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,375
Closed -$296K – 89
2021
Q2 		$296K Buy
+9,375
New +$291K 0.09% 185

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tibra Equities Europe's ELVN Position: Q3 2021 in Review

Tibra Equities Europe sold out of Enliven Therapeutics (ELVN) in Q3 2021, closing a stake of 9,375 shares — an estimated $296K sold.

Tibra Equities Europe first reported a position in ELVN in Q2 2021 and held it in 1 quarter. The position peaked at $296K in Q2 2021. 38 funds tracked by Wall St. Rank hold ELVN as of Q3 2021.

  • Tibra Equities Europe reported no remaining Enliven Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 9,375 Enliven Therapeutics shares in Q3 2021, an estimated $296K.
  • Tibra Equities Europe first reported a position in Enliven Therapeutics in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Enliven Therapeutics position peaked at $296K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.